Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Coherus Biosciences ( (CHRS) ) is now available.
Paul Reider, Coherus BioSciences’ Chief Commercial Officer, resigned effective April 30, 2025, following the company’s divestiture of its UDENYCA franchise. His departure is amicable, with no disagreements cited, and he will receive a compensation package including salary continuation and stock option extensions, while advising the company part-time until April 2026.
Spark’s Take on CHRS Stock
According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.
Coherus Biosciences presents a mixed picture. Financial challenges, particularly a weak balance sheet, are significant concerns. However, strong revenue growth and strategic moves like the UDENYCA divestiture provide a positive outlook. Technical indicators suggest some upward momentum, and the low P/E ratio signals undervaluation. Positive developments in earnings calls and corporate events contribute to a moderate overall score.
To see Spark’s full report on CHRS stock, click here.
More about Coherus Biosciences
Coherus BioSciences operates in the biotechnology industry, focusing on biosimilar products, with its last product being the UDENYCA franchise.
YTD Price Performance: -24.29%
Average Trading Volume: 2,017,280
Technical Sentiment Signal: Buy
Current Market Cap: $122.9M
See more insights into CHRS stock on TipRanks’ Stock Analysis page.